Thomas Catinazzo net worth and biography

Thomas Catinazzo Biography and Net Worth

SVP of Relay Therapeutics

Tom Catinazzo brings to Relay more than 12 years of extensive experience in the biotechnology field. Prior to Relay, he was vice president of financial planning and analysis at Foundation Medicine, where he was responsible for overseeing all aspects business planning functions. Previously, Tom worked at Aileron Therapeutics, as well as Genzyme Corporation, supporting both the renal and personalized genetic health division.

Tom holds a B.S. from Boston College.

What is Thomas Catinazzo's net worth?: The estimated net worth of Thomas Catinazzo is at least $940,163.17 as of March 27th, 2025. Mr. Catinazzo owns 374,567 shares of Relay Therapeutics stock worth more than $940,163 as of April 14th. This net worth approximation does not reflect any other assets that Mr. Catinazzo may own. Additionally, Mr. Catinazzo receives an annual salary of $663,990.00 as SVP at Relay Therapeutics. Learn More about Thomas Catinazzo's net worth.
How old is Thomas Catinazzo?: Mr. Catinazzo is currently 47 years old. There are 6 older executives and no younger executives at Relay Therapeutics. The oldest executive at Relay Therapeutics is Dr. David Elliot Shaw Ph.D., Founder, who is 73 years old. Learn More on Thomas Catinazzo's age.
What is Thomas Catinazzo's salary?: As the SVP of Relay Therapeutics, Inc., Mr. Catinazzo earns $663,990.00 per year. There are 2 executives that earn more than Mr. Catinazzo. The highest earning executive at Relay Therapeutics is Dr. Donald A. Bergstrom M.D., Ph.D., President of Research & Development, who commands a salary of $1,370,000.00 per year. Learn More on Thomas Catinazzo's salary.
How do I contact Thomas Catinazzo?: The corporate mailing address for Mr. Catinazzo and other Relay Therapeutics executives is 399 BINNEY STREET 2ND FLOOR, CAMBRIDGE MA, 02139. Relay Therapeutics can also be reached via phone at 617-370-8837 and via email at prahmer@relaytx.com. Learn More on Thomas Catinazzo's contact information.
Has Thomas Catinazzo been buying or selling shares of Relay Therapeutics?: Thomas Catinazzo has not been actively trading shares of Relay Therapeutics during the past quarter. Most recently, Thomas Catinazzo sold 4,864 shares of the business's stock in a transaction on Thursday, March 27th. The shares were sold at an average price of $2.84, for a transaction totalling $13,813.76. Following the completion of the sale, the chief financial officer now directly owns 374,567 shares of the company's stock, valued at $1,063,770.28. Learn More on Thomas Catinazzo's trading history.
Who are Relay Therapeutics' active insiders?: Relay Therapeutics' insider roster includes Brian Adams (General Counsel), Donald Bergstrom (Insider), Thomas Catinazzo (SVP), and Andy Porter (Insider). Learn More on Relay Therapeutics' active insiders.
Are insiders buying or selling shares of Relay Therapeutics?: In the last twelve months, insiders at the sold shares 26 times. They sold a total of 711,829 shares worth more than $3,564,651.81. The most recent insider tranaction occured on March, 27th when CFO Thomas Catinazzo sold 4,864 shares worth more than $13,813.76. Insiders at Relay Therapeutics own 4.3% of the company. Learn More about insider trades at Relay Therapeutics.
Information on this page was last updated on 3/27/2025.

Thomas Catinazzo Insider Trading History at Relay Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/27/2025	Sell	4,864	$2.84	$13,813.76	374,567
1/30/2025	Sell	20,791	$4.42	$91,896.22	379,431
1/28/2025	Sell	36,036	$4.63	$166,846.68	263,190
12/27/2024	Sell	4,865	$4.42	$21,503.30	299,226
10/28/2024	Sell	6,802	$6.06	$41,220.12	306,391
7/29/2024	Sell	10,780	$8.56	$92,276.80	319,650
6/27/2024	Sell	9,373	$6.24	$58,487.52	330,430
4/29/2024	Sell	1,695	$6.38	$10,814.10	339,803
3/27/2024	Sell	348	$7.70	$2,679.60	341,498
1/29/2024	Sell	2,005	$9.64	$19,328.20	341,846
12/27/2023	Sell	294	$11.51	$3,383.94	143,851
10/30/2023	Sell	1,697	$6.03	$10,232.91	144,145
9/27/2023	Sell	294	$8.38	$2,463.72	145,842
7/28/2023	Sell	1,693	$11.80	$19,977.40	146,136
6/27/2023	Sell	294	$12.12	$3,563.28	147,829
4/28/2023	Sell	863	$11.16	$9,631.08	149,272
3/27/2023	Sell	347	$15.36	$5,329.92	150,135
1/30/2023	Sell	864	$21.56	$18,627.84	150,482
12/27/2022	Sell	445	$14.49	$6,448.05	50,231
10/28/2022	Sell	1,099	$21.54	$23,672.46	50,676
9/27/2022	Sell	443	$22.73	$10,069.39	51,775
9/8/2022	Sell	26,257	$30.00	$787,710.00	52,218
7/28/2022	Sell	734	$21.26	$15,604.84	52,218
6/27/2022	Sell	300	$20.31	$6,093.00	52,952
4/28/2022	Sell	725	$25.57	$18,538.25	53,252
3/29/2022	Sell	282	$29.87	$8,423.34
3/24/2022	Sell	13,286	$30.00	$398,580.00
12/27/2021	Sell	295	$33.10	$9,764.50
11/15/2021	Sell	22,500	$35.40	$796,500.00
9/27/2021	Sell	293	$36.87	$10,802.91
9/13/2021	Sell	22,500	$35.00	$787,500.00	38,077
6/7/2021	Sell	22,500	$35.00	$787,500.00	38,370

See Full Table

Thomas Catinazzo Buying and Selling Activity at Relay Therapeutics

Relay Therapeutics Company Overview

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $2.51

$2.30

$2.51

50 Day Range

MA: $3.27

$2.00

$4.79

2 Week Range

Now: $2.51

$1.78

$10.72

Volume

1,220,976 shs

Average Volume

1,955,760 shs

Market Capitalization

$425.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.7

Thomas Catinazzo Biography and Net Worth

What is Thomas Catinazzo's net worth?

How old is Thomas Catinazzo?

What is Thomas Catinazzo's salary?

How do I contact Thomas Catinazzo?

Has Thomas Catinazzo been buying or selling shares of Relay Therapeutics?

Who are Relay Therapeutics' active insiders?

Are insiders buying or selling shares of Relay Therapeutics?